Categories: News

BingX Launches $150M Shield Fund to Set a New Benchmark for User Protection

PANAMA CITY, June 5, 2025 /PRNewswire/ — BingX, a leading global cryptocurrency exchange and Web3 AI company, has introduced the Shield Fund, a permanent $150 million safety reserve dedicated to safeguarding users against unforeseen cyber threats and extreme market volatility. Unlike conventional insurance models, the Shield Fund is entirely self-funded and always active, enabling BingX to respond swiftly during crises. This initiative underscores BingX’s commitment to transparency, accountability, and its unwavering user-first vision.

- Advertisement -

Built with long-term sustainability in mind, the Shield Fund features continuous internal audits and dynamic risk assessments to adapt to evolving market conditions. It offers BingX users an added layer of real-time protection and peace of mind, solidifying BingX’s position as a leader in secure and responsible crypto trading.

- Advertisement -

“The launch of the BingX Shield Fund is a strategic extension of our user-first vision. It is not simply a financial safeguard — it is a symbol of how we view responsibility at scale,” said Vivien Lin, Chief Product Officer at BingX. “We are reaffirming our commitment to building a secure, transparent, and forward-thinking trading environment. As our platform grows, so does our duty to empower users with tools and systems that ensure confidence, resilience, and long-term trust.”

- Advertisement -

Following the implementation of Proof-of-Reserve, the Shield Fund represents the next chapter in BingX’s ongoing mission to elevate platform integrity and user protection. Together, these initiatives form a robust foundation for a more transparent, secure, and accountable trading environment. Looking ahead, BingX remains committed to delivering proactive safety measures and pioneering infrastructure innovations to safeguard user interests.

- Advertisement -

About BingX 

- Advertisement -

Founded in 2018, BingX is a leading crypto exchange and Web3 AI company, serving a global community of over 20 million users. With a comprehensive suite of AI-powered products and services, including derivatives, spot trading, and copy trading, BingX caters to the evolving needs of users across all experience levels, from beginners to professionals. Committed to building a trustworthy and intelligent trading platform, BingX empowers users with innovative tools designed to enhance performance and confidence. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports sponsorship.

- Advertisement -

For more information please visit: https://bingx.com/

- Advertisement -

Photo – https://mma.prnewswire.com/media/2704170/1280_675_blank.jpg 
Logo – https://mma.prnewswire.com/media/2310183/BingX_logo_Logo.jpg

- Advertisement -

 

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/bingx-launches-150m-shield-fund-to-set-a-new-benchmark-for-user-protection-302474266.html

- Advertisement -

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

8 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

8 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

8 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

8 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

8 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

8 hours ago